By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751



Company News
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 7/1/2015 11:43:48 AM
Sarepta (SRPT) Appoints Henri Termeer As Advisor To The Company 7/1/2015 11:21:59 AM
Sarepta (SRPT) Bags Ex-Genzyme (GENZ) CEO as Advisor to the Company 7/1/2015 6:46:12 AM
New Sarepta (SRPT) CEO's Strategy Bears Fruit With NDA Filing 6/30/2015 6:24:24 AM
Sarepta (SRPT) Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 6/29/2015 12:44:38 PM
Sarepta (SRPT) Secures $40 Million In Debt Financing 6/29/2015 12:26:55 PM
EXCLUSIVE: Sarepta (SRPT)'s Interim CEO Doing Well Enough to Be Considered a Permanent Candidate, Company Tells BioSpace (DHX) 6/2/2015 8:08:56 AM
Sarepta (SRPT) Announces Plans To Submit Rolling NDA For Eteplirsen Following Today‚Äôs Pre-NDA Meeting With The FDA 5/20/2015 6:02:25 AM
Wall Street Cheers As Sarepta (SRPT) Soars 50% Premarket on Muscular Dystrophy Drug Filing 5/20/2015 6:01:00 AM
Sarepta (SRPT) Announces First Quarter 2015 Financial Results And Recent Corporate Developments 5/7/2015 12:50:06 PM